Medexus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.4
- Today's High:
- $2.562
- Open Price:
- $2.445
- 52W Low:
- $0.585
- 52W High:
- $2.562
- Prev. Close:
- $2.47
- Volume:
- 2249
Company Statistics
- Market Cap.:
- $43.68 million
- Book Value:
- 1.121
- Revenue TTM:
- $116.61 million
- Operating Margin TTM:
- 11.38%
- Gross Profit TTM:
- $65.77 million
- Profit Margin:
- 2.8%
- Return on Assets TTM:
- 5.47%
- Return on Equity TTM:
- 16.23%
Company Profile
Medexus Pharmaceuticals Inc had its IPO on under the ticker symbol MEDXF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Medexus Pharmaceuticals Inc has a staff strength of 98 employees.
Stock update
Shares of Medexus Pharmaceuticals Inc opened at $2.45 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.4 - $2.56, and closed at $2.53.
This is a +2.43% increase from the previous day's closing price.
A total volume of 2,249 shares were traded at the close of the day’s session.
In the last one week, shares of Medexus Pharmaceuticals Inc have increased by +18.22%.
Medexus Pharmaceuticals Inc's Key Ratios
Medexus Pharmaceuticals Inc has a market cap of $43.68 million, indicating a price to book ratio of 1.747 and a price to sales ratio of 0.3067.
In the last 12-months Medexus Pharmaceuticals Inc’s revenue was $116.61 million with a gross profit of $65.77 million and an EBITDA of $19.03 million. The EBITDA ratio measures Medexus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Medexus Pharmaceuticals Inc’s operating margin was 11.38% while its return on assets stood at 5.47% with a return of equity of 16.23%.
In Q2, Medexus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 36.9%.
Medexus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 133.3333
- Trailing PE
- 13.375
- PEG
Its diluted EPS in the last 12-months stands at $0.16 per share while it has a forward price to earnings multiple of 133.3333 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Medexus Pharmaceuticals Inc’s profitability.
Medexus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.8716 and a EV to EBITDA ratio of 8.1568. Its price to sales ratio in the trailing 12-months stood at 0.3067.
Medexus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $166.87 million
- Total Liabilities
- $90.58 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $28000
- Dividend Payout Ratio
- 0%
Medexus Pharmaceuticals Inc ended 2024 with $166.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $166.87 million while shareholder equity stood at $22.73 million.
Medexus Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $90.58 million in other current liabilities, in common stock, $-63377000.00 in retained earnings and $10.39 million in goodwill. Its cash balance stood at $15.78 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $25.44 million.
Medexus Pharmaceuticals Inc’s total current assets stands at $79.50 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $25.95 million compared to accounts payable of $34.85 million and inventory worth $25.00 million.
In 2024, Medexus Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $28000.
Comparatively, Medexus Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.53
- 52-Week High
- $2.562
- 52-Week Low
- $0.585
- Analyst Target Price
- $
Medexus Pharmaceuticals Inc stock is currently trading at $2.53 per share. It touched a 52-week high of $2.562 and a 52-week low of $2.562. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $1.91 and 200-day moving average was $1.39 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 1194.1% of the company’s stock are held by insiders while 553.5% are held by institutions.
Frequently Asked Questions About Medexus Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.